Results in Adults

How DUPIXENT May Help

DUPIXENT was studied in 3 clinical trials with more than 2,100 adults with uncontrolled moderate-to-severe eczema (atopic dermatitis).

What You Should Know About the Adult Patients in These Studies:

52%
had moderate atopic dermatitis
48%
had severe atopic dermatitis
≈38 years
Average age
≈28 years
Average duration of the disease
≈55%
Average body surface area involvement

Results in two 16-week adult clinical trials with DUPIXENT when used alone compared to a placebo

Nearly half of adult patients saw 75%
skin improvement and some even saw
90% improvement
Almost 4 times more adult patients taking DUPIXENT saw clear or almost clear skin as compared with those not taking DUPIXENT (37% taking DUPIXENT as compared to 9% taking placebo)
Adult patients experienced significant
itch reduction, some patients as early as
2 weeks
The most common side effects in adult patients were injection site reactions, eye and eyelid inflammation, including redness, swelling and itching, and cold sores in your mouth or on your lips.
Quick Tips
  • Photograph your skin regularly; this may help you determine if DUPIXENT is having an impact.
  • Jot down your symptoms of uncontrolled moderate-to-severe eczema that you feel each month. Can you tell if your itching has decreased?

Get Down to the Details

Expand the boxes below to see more detailed results from the 3 clinical studies with adults.

Results at 16 weeks when DUPIXENT was used alone*† compared to adult patients taking placebo

DUPIXENT Not taking DUPIXENT (taking placebo)

37% of adult patients had clear or almost clear skin compared to 9% taking placebo

48% of adult patients showed a 75% improvement in their skin compared to 13% taking placebo

33% of adult patients showed a 90% improvement in their skin compared to 7% taking placebo

*Results from "DUPIXENT alone" represents the average results from 2 studies

†All patients used a daily moisturizer

Results at 16 weeks when DUPIXENT was used every other week with topical corticosteroids compared to adult patients taking topical corticosteroids

DUPIXENT + topical corticosteroids Not taking DUPIXENT (taking placebo + topical corticosteroids)

39% of adult patients had clear or almost clear skin when DUPIXENT was used with topical corticosteroids compared to 12% taking placebo with topical corticosteroids

69% of adult patients showed a 75% improvement in their skin when DUPIXENT was used with topical corticosteroids compared to 23% taking placebo with topical corticosteroids

40% of adult patients showed a 90% improvement in their skin when DUPIXENT was used with topical corticosteroids compared to 11% taking placebo with topical corticosteroids

Adult patients experienced a significant itch reduction while
participating in clinical trials

DUPIXENT Not taking DUPIXENT (taking placebo)

38% of adult patients had significant itch reduction at 16 weeks when DUPIXENT was used alone compared to 11% taking placebo

DUPIXENT + topical corticosteroids Not taking DUPIXENT (taking placebo + topical corticosteroids)

59% of adult patients had significant itch reduction at 16 weeks when DUPIXENT was used with topical corticosteroids compared to 20% taking placebo with topical corticosteroids

Results represent the average results of 2 studies

DUPIXENT started working quickly (as early as 2 weeks) and continued to show results, with the majority of adult patients seeing significant skin improvement and itch reduction at 1 year of treatment when used with topical corticosteroids.

These results show the percentage of adult patients who experienced the following results at 1 year (52 weeks) while taking DUPIXENT once every other week while using topical corticosteroids compared to patients taking placebo and topical corticosteroids.

DUPIXENT + topical corticosteroids Not taking DUPIXENT (taking placebo + topical corticosteroids)

36% of adult patients had clear or almost clear skin when DUPIXENT was used with topical corticosteroids compared to 13% taking placebo with topical corticosteroids

65% of adult patients saw a 75% improvement in their skin when DUPIXENT was used with topical corticosteroids compared to 22% taking placebo with topical corticosteroids

51% of adult patients had significant itch reduction at 1 year when DUPIXENT was used with topical corticosteroids compared to 13% taking placebo with topical corticosteroids

The safety profile of DUPIXENT and topical corticosteroids through Week 52 (trial 3) in adults was generally consistent with the safety profile observed at Week 16.

Find a Specialist Who
Treats Eczema

Use this Healthgrades™ tool to easily find nearby specialists with experience in treating teens and adults with uncontrolled moderate-to-severe eczema (atopic dermatitis).

Sanofi US and Regeneron do not endorse or recommend any particular physician, and search results do not include a comprehensive list of doctors in your area.
Sanofi US and Regeneron do not endorse or recommend any particular physician, and search results do not include a comprehensive list of doctors in your area.
Have an Effective Conversation With
Your Doctor

Our goal is for you to get the most out of your visit to the doctor. Download the discussion guide for tips on how to drive a productive conversation.

Doctor Discussion Guide 234 KB
DUPIXENT is given as an injection under the skin (subcutaneous). Read the instructions for use or watch a video on how to take it.

Get the Instructions